Celldex Therapeutics Inc. (CLDX) Plunges 11.39% on April 02

Celldex Therapeutics Inc. (CLDX) Plunges 11.39% on April 02

Celldex Therapeutics Inc. (CLDX) had a rough trading day for Tuesday April 02 as shares tumbled 11.39%, or a loss of $-0.58 per share, to close at $4.51. After opening the day at $4.71, shares of Celldex Therapeutics Inc. traded as high as $4.79 and as low as $4.46. Volume was 1.26 million shares over 4,274 trades, against an average daily volume of n/a shares and a total float of 12.44 million.

As a result of the decline, Celldex Therapeutics Inc. now has a market cap of $56.1 million. In the last year, shares of Celldex Therapeutics Inc. have traded between a range of $34.95 and $2.75, and its 50-day SMA is currently $n/a and 200-day SMA is $n/a.

Celldex Therapeutics Inc is a biopharmaceutical company. It is focused on the development and commercialization of several immunotherapy technologies and other cancer-targeting biologics. The company is also engaged in clinical trials for products targeting breast cancer, metastatic melanoma, lung cancer, solid tumors, and ovarian cancer. Its pipeline products are Varlilumab, CDX-301, CDX-1140, and CDX-3379.

Celldex Therapeutics Inc. is based out of Hampton, NJ and has some 135 employees. Its CEO is Anthony S. Marucci.

Share:
Scroll Up
error: Content is protected !!